1
|
Rapti I, Asimakopoulos A, Liontos A, Kosmidou M, Christaki E, Biros D, Milionis O, Tsourlos S, Ntotsikas E, Ntzani E, Evangelou E, Gartzonika K, Georgiou I, Tzoulaki I, Tsilidis K, Milionis H. Association of patient characteristics with clinical outcomes in a cohort of hospitalised patients with SARS-CoV-2 infection in a Greek referral centre for COVID-19 - Corrigendum. Epidemiol Infect 2023; 151:e91. [PMID: 37288502 DOI: 10.1017/s0950268823000857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Open
Affiliation(s)
- I Rapti
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - A Asimakopoulos
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
| | - A Liontos
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - M Kosmidou
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - E Christaki
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - D Biros
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - O Milionis
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - S Tsourlos
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| | - E Ntotsikas
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
| | - E Ntzani
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Center for Evidence-Based Medicine, Department of Health Services, Policy and Practice, School of Public Health, Brown University, Providence, RI, USA
| | - E Evangelou
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - K Gartzonika
- Microbiology Department, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina45110, Greece
| | - I Georgiou
- Genetics and IVF Unit, Department of Obstetrics and Gynaecology, Medical School, University of Ioannina, Ioannina45110, Greece
| | - I Tzoulaki
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - K Tsilidis
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - H Milionis
- Department of Internal Medicine, Ioannina University Hospital, University of Ioannina, Ioannina, Greece
| |
Collapse
|
2
|
Liontos A, Biros D, Papathanasiou A, Papagiannopoulos C, Klouras E, Veliani C, Kolios NG, Pappa C, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The effect of various antihypertensive drugs on the glucose homeostasis has been discussed extensively. Dual combination treatment is advised with current guidelines. We present comparative data of the effect of delapril/manidipine versus valsartan/amlodipine versus telmisartan/amlodipine combination treatments, in fasting glucose, fasting insulin, OGTT and HbA1c levels, before and after the 3-month treatment, in hypertensive prediabetic patients.
Methods
Data were collected from 154 patients from the outpatient clinic for patients with lipid disorders, hypertension and diabetes of our hospital, during the period 2014–2018. A number of 53 persons was randomized in the delapril/manidipine group 30/10 mg per day while 51 persons had been randomized in the group of telmisartan/amlodipine 80/5mg per day and 54 patients in the valsartan/amlodipine 160/5 mg per day. All patients successfully completed the study. Baseline characteristics are presented in Table 1A.
Results
The resulting alternations in glucose, insulin, OGTT and HbA1c levels, before and after the 3-month treatment are presented on Table 1B for the 3 groups of treatment.
Conclusions
In the comparison between the groups, a statistically significant difference was found in the change in INS values from the beginning of treatment until 3 months, for the TEL/AMLO treatment group, where a statistically significant difference from the DEL/MANI treatment group (p-value<0.01) and a strong statistically significant difference from the VAL/AMLO treatment group (p-value<0.001) were noted. The TEL/AMLO group had the only decrease in insulin levels compared to the other treatment groups where an increase was observed, after the treatment. The change in OGTT levels showed a statistically significant difference (p-value<0.05) between the DEL/MANI treatment group (a decrease of 6.63%) compared to the TEL/AMLO treatment group (an increase of 1.53%) after 3 months of treatment.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Liontos
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - D Biros
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - A Papathanasiou
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | | | - E Klouras
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - C Veliani
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - N G Kolios
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - C Pappa
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | | | - M Elisaf
- University hospital of Ioannina, 2nd Division of Internal Medicine , Ioannina , Greece
| | - H Milionis
- University hospital of Ioannina, 1st Division of Internal Medicine and infectious Diseases Unit , Ioannina , Greece
| | - G Liamis
- University hospital of Ioannina, 2nd Division of Internal Medicine , Ioannina , Greece
| |
Collapse
|
3
|
Liontos A, Filippas-Ntekouan S, Biros D, Kolios NG, Papagiannopoulos C, Veliani C, Papathanasiou A, Samanidou V, Tsourlos S, Athanasiou L, Pappa C, Pargana E, Nasiou M, Zarachi A, Vagias I, Tsiakas I, Christaki E, Elisaf M, Liberopoulos E, Milionis H, Liamis G. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Liontos A, Biros D, Papathanasiou A, Papagiannopoulos C, Klouras E, Tsourlos S, Athanasiou L, Filippas-Ntekouan S, Zarachi A, Kolios NG, Pappa C, Samanidou V, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Liontos A, Biros D, Papathanasiou A, Papagiannopoulos C, Klouras E, Athanasiou L, Tsourlos S, Filippas-Ntekouan S, Samanidou V, Kolios NG, Veliani C, Pappa C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
6
|
Liontos A, Filippas-Ntekouan S, Biros D, Kolios NG, Veliani C, Papagiannopoulos C, Samanidou V, Papathanasiou A, Tsourlos S, Athanasiou L, Pappa C, Pargana E, Nasiou M, Zarachi A, Tsiakas I, Christaki E, Elisaf M, Liberopoulos E, Milionis H, Liamis G. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Zarachi A, Kolios NG, Pargana E, Nasiou M, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with telmisartan/amlodipine in prediabetic patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of telmisartan with amlodipine is a commonly administered combination of an agonist ATII (angiotensin receptor II) and CCB (calcium channel blocker) for the management of hypertension. The purpose of this study is to evaluate the effect of the fixed of combination telmisartan/amlodipine 80/5mg per day on the levels of serum lipids, as well as the levels of serum apolipoproteins and the TRG/ApoA-1, TRG/HDL-C ratios, in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-180 mmHg and/or diastolic blood pressure (DBP) 100-110 mmHg) and with prediabetes (IFG/IGT), before and after the 3-month treatment.
Methods
Data from 51 patients who had visited our outpatient clinic for lipid metabolism disorders during the period 2014-2018 and had been randomized in the telmisartan/amlodipine group 80/5mg per day. The patients (35 male/16 female) had BMI: 29.32 [27.37-31.65]. The levels serum lipids and of apolipoproteins B, A1, Lp(a) and E were measured before the beginning of the treatment and 3-months after its administration.
Results
The resulting variations of SBP and DBP levels before and after the 3-month treatment, as well as the variations of serum lipid, apolipoprotein levels and TRG/ApoA-1, TRG/HDL-C ratios are presented on Table 1.
Conclusion
The 3-month telmisartan/amlodipine therapy seems to improved, statistically significant both SBP and DBP levels (decreased by -13.58 % and -13 % respectively, p<0.001, for both values). Serum lipid levels didn’t show any significant variation before and after treatment. Statistically significant changes were not present in apolipoprotein levels, also. Finally, there were no statistically significant variations in either TRG/ApoA-1 or TRG/HDL-C ratios.
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Pargana
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - M Nasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
8
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Kolios NG, Pappa C, Veliani C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with delapril/manidipine in prediabetic hypertensive patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Purpose
The administration of the 30mg hydrochloric delapril and 10mg hydrochloric manidipine formulation is indicated for patients with idiopathic hypertension whose arterial pressure cannot be sufficiently managed with monotherapy. The purpose of this study is to investigate the effect of the premade combination delapril/manidipine 30/10mg per day on the variation of HOMA-IR, HOMA-B and QUICKI values, in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-180 mmHg and/or diastolic blood pressure (DBP) 100-110 mmHg) and with prediabetes (IFG/IGT) before and after the 3-month treatment with the fixed combination dual-therapy.
Methods
53 patients (30 male/23 female, from whom 12 smokers and 7 alcohol users) who visited our outpatient clinic for lipid metabolism disorders and fulfilled the study’s criteria joined the study’s sample. They were randomized in the delapril/manidipine group. The patients’ BMI was 28.73 [27.73-30.3] and the SBP and DBP values were: 156 [151-161] and 100 [88-101] mmHg respectively.
Results
The resulting variations of SBP and DBP levels, as well as the variations of glucose and insulin levels and HOMA-IR, HOMA-B and QUICKI are presented on Table 1.
Results
From the sampled patients it seems that the 3-month treatment with delapril/manidipine improved statistically significantly the levels of both SBP and DBP (reduction by -11.54% and -12% respectively, p<0.001 for both values). Glucose levels witnessed a 1.55% decrease with statistical significance while a notable increase in insulin by 4.65% was also observed after the 3-month treatment, albeit without any statistical significance. Concerning HOMA-IR and QUICKI, there were no significant variance, while HOMA-B values showed a statistically significant increase (7%, p=0.006)
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Pappa
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
9
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Veliani C, Kolios NG, Pappa C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with telmisartan/amlodipine in prediabetic hypertensive patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of telmisartan and amlodipine in tablet form indicated for patients whose arterial blood pressure cannot be fully managed with monotreatment. The purpose of this study was to investigate the effect of the fixed combination telmisartan/amlodipine 80/5mg per day on arterial pressure levels and the variation of HOMA-IR, HOMA-B and QUICKI values in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-179 mmHg and/or diastolic blood pressure (DBP) 100-109 mmHg) and with prediabetes (IFG/IGT) before and after the 3-month treatment with the administration of the fixed combination.
Methods
Data collected from 51 patients who have visited our outpatient clinic for lipid metabolism disorders during the period 2014-2018. 51 persons with BMI: 29.32 [27.37-31.65] (25 male, 16 female) had been randomized in the group for telmisartan/amlodipine 80/5mg per day.
The median values for the study’s sample in SBP and DBP were: 163[158-168] and 100[95-106] mmHg, respectively. Their somatometric and demographic characteristics were recorded in the beginning of the study and are presented on Table 1Α.
Results
The results of the variations in SBP and DBP, as well as the variations in glucose, insulin, HOMA-IR, HOMA-B and QUICKI before and after the 3-month treatment are presented on Table 1B.
Conclusions
From the sampled patients it can be observed that the 3-month treatment with telmisartan/amlodipine statistically significantly improved (p=0.005) the HOMA-IR values while improving fasting glucose and insulin levels. Finally, there was a statistically significant reduction in QUICKI values and a statistically insignificant reduction in HOMA-B.
Collapse
Affiliation(s)
- A Liontos
- University hospital of Ioannina, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Pappa
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
10
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Athanasiou L, Tsourlos S, Veliani C, Kolios NG, Pappa C, Zarachi A, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with valsartan/amlodipine in prediabetic hypertensive patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of valsartan with amlodipine is more effective than monotherapy for managing HT. The purpose of this study was to investigate the effect of the fixed combination of valsartan/amlodipine 160/5 mg per day on HOMA-IR (homeostatic model assessment for insulin resistance), HOMA-B (HOMA for β cell function) and QUICKI (quantitative insulin-sensitivity check index) values in patients with stage 2 hypertension (systolic arterial pressure 160-179 mmHg and/or diastolic pressure 100-109 mmHg) and prediabetes (IFG/IGT) before and after 3 months of treatment with the dual therapy.
Methods
Data from 54 patients who visited our outpatient clinic for lipid metabolism during the period 2014-2018. 54 persons were randomized in the valsartan/amlodipine group 160/5 mg per day (33 males/21 females from whom 14 were smokers and 8 were alcohol consumers) with BMI: 28.09[26.81-29.89], all of whom successfully completed the study. The median values of systolic and diastolic arterial pressure for the study population: 162 [159.25-165] and 100 [92-103.75] mmHg, respectively.
Results
The resulting variations of systolic and diastolic arterial pressure as well as the variations of HOMA-IR, HOMA-B and QUICKI are presented on Table 1.
Conclusions
From the studied group it is concluded that the 3-month treatment with valsartan/amlodipine improved with statistical significance the values of both systolic and diastolic arterial pressure (reduction by -13.58% and -13% for systolic and diastolic arterial pressure, respectively, p<0.001, for both values). Regarding glucose levels, there has also been a reduction by -0.04%, without statistical significance, while the increase of insulin levels (+16.13%) by the end of the 3-month period was also deemed statistically insignificant. Additionally, there have been noted statistically insignificant increases in HOMA-IR (+12.65%) and HOMA-B (+17%). Finally, no change has been observed in QUICKI values.
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - NG Kolios
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Pappa
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
11
|
Liontos A, Papathanasiou A, Biros D, Papagiannopoulos C, Tsourlos S, Athanasiou L, Zarachi A, Pargana E, Nasiou M, Veliani C, Christaki E, Liberopoulos E, Elisaf M, Milionis H, Liamis G. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with valsartan/amlodipine in prediabetic patients. Eur J Prev Cardiol 2022. [DOI: 10.1093/eurjpc/zwac056.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction-Purpose
The combination of valsartan with amlodipine is a commonly administered combination of an agonist ATII (angiotensin receptor II) and CCB (calcium channel blocker) for the management of hypertension. There is already data from different studies that describe the effect of each of those medications in the lipidemic profile. Ratios TRG/ApoA-1, TRG/HDLC are useful markers of insulin resistance. The purpose of this study is to investigate the effect of the fixed combination of valsartan/amlodipine 160/5mg per day on the levels of serum lipids, as well as the levels of serum apolipoproteins and the TRG/ApoA-1, TRG/HDLC ratios, in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-179 mmHg and/or diastolic blood pressure (DBP) 100-109 mmHg) and prediabetes (IFG/IGT), before and after the 3-month treatment.
Methods
Data from 54 patients who were referred to our outpatient clinic for lipid metabolism disorders during the period 2014-2018 and had been randomized in the valsartan/amlodipine group 160/5mg per day. Those patients (33 male/21 female from whom 14 were smokers and 8 alcohol users) all completed the study successfully with mean BMI: 28.09[26.81-29.89]. The median values of SBP and DBP for the sample group were: 162 [159.25-165] και 100 [92-103.75] mmHg, respectively. The levels of apolipoproteins B, A-1, Lp(a) and E were measured prior to the beginning of treatment and 3-months after its administration.
Results
The resulting alternations of SBP and DBP levels before and after the 3-month treatment, as well as the changes of serum lipid, apolipoprotein levels and TRG/ApoA-1, TRG/HDL-C ratios are presented in Table 1.
Conclusions
From the sample group it seems like that the 3-month therapy with valsartan/amlodipine improved statistically significant both SBP and DBP levels (decreased by -13.58% and -13% respectively, p<0.001 for both values). Concerning lipid levels, no significant variation was observed across the board. Finally, no significant change was observed in apolipoprotein levels and TRG/ApoA-1, TRG/HDL-C ratios.
Collapse
Affiliation(s)
- A Liontos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Papathanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - D Biros
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | | | - S Tsourlos
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - L Athanasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - A Zarachi
- University Hospital of Ioannina, ENT departement, Ioannina, Greece
| | - E Pargana
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - M Nasiou
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - C Veliani
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Christaki
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - E Liberopoulos
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - M Elisaf
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| | - H Milionis
- University Hospital of Ioannina, 1st Division of Internal Medicine, Ioannina, Greece
| | - G Liamis
- University Hospital of Ioannina, 2nd Division of Internal Medicine, Ioannina, Greece
| |
Collapse
|
12
|
Barkas F, Elisaf M, Liberopoulos E, Klouras E, Kei A, Liontos A, Megapanou E, Lamouri C, Rizos E. Non-alcoholic fatty liver disease and its association with incident diabetes in statin-treated individuals. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Liamis G, Filippatos TD, Liontos A, Elisaf MS. MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment. Eur J Endocrinol 2017; 176:R15-R20. [PMID: 27484454 DOI: 10.1530/eje-16-0493] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Revised: 07/06/2016] [Accepted: 08/01/2016] [Indexed: 12/11/2022]
Abstract
BACKGROUND Patients with moderate to severe hypothyroidism and mainly patients with myxedema may exhibit reduced sodium levels (<135 mmol/L). SUMMARY The aim of this short review is the presentation of the mechanisms of hyponatremia and of the available data regarding its implications and treatment in patients with hypothyroidism. Hypothyroidism is one of the causes of hyponatremia, thus thyroid-stimulating hormone determination is mandatory during the evaluation of patients with reduced serum sodium levels. The main mechanism for the development of hyponatremia in patients with chronic hypothyroidism is the decreased capacity of free water excretion due to elevated antidiuretic hormone levels, which are mainly attributed to the hypothyroidism-induced decrease in cardiac output. However, recent data suggest that the hypothyroidism-induced hyponatremia is rather rare and probably occurs only in severe hypothyroidism and myxedema. Other possible causes and superimposed factors of hyponatremia (e.g. drugs, infections, adrenal insufficiency) should be considered in patients with mild/moderate hypothyroidism. Treatment of hypothyroidism and fluid restriction are usually adequate for the management of mild hyponatremia in patients with hypothyroidism. Patients with possible hyponatremic encephalopathy should be urgently treated according to current guidelines. CONCLUSIONS Severe hypothyroidism may be the cause of hyponatremia. All hypothyroid patients with low serum sodium levels should be evaluated for other causes and superimposed factors of hyponatremia and treated accordingly.
Collapse
Affiliation(s)
- G Liamis
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| | - T D Filippatos
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| | - A Liontos
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| | - M S Elisaf
- Department of Internal MedicineSchool of Medicine, University of Ioannina, Ioannina, Greece
| |
Collapse
|
14
|
Christogiannis L, Kostapanos M, Kostara C, Barkas F, Liontos A, Panagiotopoulou T, Bairaktari E, Elisaf M. Effects of combinations of valsartan with amlodipine or hydrochlorothiazide on renal function and proteinuria in hypertensive patients with metabolic syndrome. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|